No Data
INNOCARE (09969.HK) spent HKD 2.2532 million to repurchase 0.4 million shares on January 23.
Gelonghui reported on January 23 that INNOCARE (09969.HK) announced the repurchase of 0.4 million shares at a cost of 2.2532 million Hong Kong dollars on January 23, 2025, with a repurchase price of 5.57-5.76 Hong Kong dollars per share.
INNOCARE (09969.HK) spent 2.4395 million Hong Kong dollars to repurchase 0.426 million shares on January 22.
Gelonghui reported on January 22 that INNOCARE (09969.HK) announced that on January 22, 2025, it spent 2.4395 million Hong Kong dollars to repurchase 0.426 million shares, with the repurchase price per share being 5.66-5.74 Hong Kong dollars.
InnoCare Pharma Appoints Renowned Scientist as Independent Director
InnoCare Pharma Updates Board of Directors and Roles
INNOCARE (09969.HK) has appointed Guan Kunliang as an independent non-executive Director.
On January 21, Gelonghui reported that INNOCARE (09969.HK) announced that Professor Guan Kunliang has been appointed as an independent non-executive director, effective from January 21, 2025. Professor Guan is primarily responsible for overseeing the Board of Directors and providing independent judgment to it.
INNOCARE collaborates with Cannovia "NewCo" for international expansion, potentially receiving over $0.5 billion in milestone payments.
① INNOCARE and Kangnuoya will collectively receive an initial and recent payment of 17.5 million USD at a ratio of 50% each, and will also acquire minority shares in Prolium; ② In recent years, the NewCo model trade boom has emerged, which has dual attributes of financing and business development, providing innovative drug companies with an alternative path to go abroad, apart from the traditional license out.
